ERC Consolidator Grant · 2025
Rerouting mRNA for in vivo chimeric antigen receptor immune cell therapy
Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment. Nevertheless, CAR T cell therapy is clinically limited to hematological malignancies and hampered by its complex and costly ex vivo manufacturing procedure. To render this treatment cost-effective and available for diverse cancer types, in vivo CAR immune cell therapy strategies must be developed. My group has established new apolipoprotein nanoparticle (aNP) platform technology for RNA delivery to immune cells. Leveraging lipoproteins’ natural delivery features, our technology combines tunable biodistribution features with a superb biocompatibility profile. Building on this concept, I propose developing…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.